Predictors of bleeding complications after rescue coronary interventions

Journal of Thrombosis and Thrombolysis

Volumn 10, Issue 1, 2000, Pages 83-88

  Dauerman, H L ^a   Andreou, C ^a   Perras, M A ^a   Spinner, J S ^a   Lessard, D ^a   Weiner, B H ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Angioplasty; Bleeding; Thrombolysis

Indexed keywords

ABCIXIMAB; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; STREPTOKINASE;

ADULT; AGE; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CARDIOGENIC SHOCK; CORONARY STENT; FEMALE; GENDER; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK FACTOR;

EID: 0033798143     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018759024035     Document Type: Article

References (27)

1. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction
2. ISIS-3: A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction
3. Evaluation of a weight-adjusted single-bolus plasminogen activator in patients with myocardial infarction: A double-blind, randomized angiographic trial of lanoteplase versus alteplase
4. Should thrombolysis or primary angioplasty be the treatment of choice for acute myocardial infarction? Primary angioplasty-the strategy of choice
5. A prospective, placebo-controlled, randomized trial of intravenous streptokinase and angioplasty versus lone angioplasty therapy of acute myocardial infarction
6. Comparison of immediate invasive, delayed invasive, and conservative strategies after tissue-type plasminogen activator. Results of the thrombolysis in myocardial infarction (TIMI) phase II-A trial
7. Rescue angioplasty after failed thrombolysis: Technical and clinical outcomes in a large thrombolysis trial. GUSTO-1 Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries
8. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/III a blockade. Evaluation of platelet IIb/IIa inhibitor for stenting
9. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators
10. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
11. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet Glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy
12. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators
13. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease
14. A clinical trial comparing primary stenting of the infarct-related artery with optimal primary angioplasty for acute myocardial infarction: Results from the Florence randomized elective stenting in acute coronary occlusions (FRESCO) trial
15. Clinical and angiographic follow-up after primary stenting in acute myocardial infarction: The primary angioplasty in myocardial infarction (PAMI) stent pilot trial
16. Incidence of bleeding complications associated with abciximab use in conjunction with thrombolytic therapy in patients requiring percutaneous transluminal coronary angioplasty
17. Coronary stenting during rescue angioplasty after failed thrombolysis
18. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting
19. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction
20. A matched comparison of the combination of prehospital thrombolysis and standby rescue angioplasty with primary angioplasty
21. Prospective, multicenter study of the safety and feasibility of primary stenting in acute myocardial infarction: In hospital and 30-day results of the PAMI stent pilot trial. Primary Angioplasty in Myocardial Infarction Stent Pilot Trial Investigators
22. Thrombolytic therapy: Current status (2)
23. Thrombolytic therapy: Current status (2)
24. Importance of the pharmacological profile of thrombolytic agents in clinical practice
25. Abciximab facilities the rate and extent of thrombolysis: Results of the thrombolysis in myocardial infarction (TIMI) 14 trial
26. Modifiable risk factors for vascular access site complications in the IMPACT II Trial of angioplasty with versus with out eptifibatide. Integrilin to minimize platelet aggregation and coronary thrombosis
27. The EPIC Investigation. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty